Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QH103 in Adult Relapsed/Refractory B-cell Lymphoma
NCT07367685Phase 1Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QH103E in B cell lymphoma, sponsored by The Second Affiliated Hospital of Fujian Medical University. Primary endpoints: Incidence of Adverse Events at 12 months, Incidence of Dose-Limiting Toxicities at 28 days and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
QH103E
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07367685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07367685.